Dengue Treatment Market, 2012-2023
Market Introduction: Dengue Treatment Market
Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue hemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications.
Market Dynamics: Dengue Treatment Market
Global dengue treatment market anticipated surging its growth owing to rise in dengue burden in tropical and sub-tropical regions, increased government funding to fight against dengue, and unmet market needs of managing dengue burden around the world. In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. However, lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and the high-cost of treatment are hindering the dengue-treatment market.
Market Segmentation: Dengue Treatment Market
Dengue Treatment Market has been segmented on the basis of drug class and distribution channel
Based on drug class, dengue Treatment market is segmented into
Dengue Treatment market is expected to grow at a significant rate during forecast period. According to World Health Organization (WHO) estimates, 50 to 100 Mn infections occur annually, including 500,000 DHF cases and 22,000 deaths, mostly among children. Dengue treatment market is at developing stage. Market players collaborating to other companies or research institutions for the development of drugs for treating the dengue. For instance, in August 2013, Johnson and Johnson Services Inc. collaborated with biotechnology nonprofit organization The Wellcome Trust, for the development of prevention and treatment therapies for dengue fever.
Regional Overview: Dengue Treatment Market
Geographically Dengue Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East &Africa. Latin America market expected to grow owing to increased dengue cases. According to WHO, in 2010, 1.6 million cases of dengue were reported in the Americas alone. In Asia-Pacific region, dengue treatment market expected to grow at a high rate due to increase in dengue coupled with an increase in government funding for dengue prevention and treatment. Market players in Asia are actively participating in develepment of dengue treating drugs to increase their market share. For instance, in May 2016, Sun Pharma collaborated with International Centre of Genetic Engineering and Biotechnology (ICGEB) to develep drug for treatment of dengue. South East Asia and Western Pacific regions are more seriously affected by dengue. Hence, companies are planning to launch their vaccines in South East Asia regions.
Market Participants: Dengue Treatment Market
Some of the market players in Dengue treatment market include F. Hoffmann-La Roche AG (Switzerland), Sun Pharmaceutical Industries Limited (India), Abbivax (France), Takeda Pharmaceutical Company Ltd (Japan), Merck & Co Inc. (U.S.), and VABIOTECH (Vietnam) to name a few.
Key Market Developments: Dengue Treatment Market
In September 2017, Abbivax and Evotec AG entered into strategic partnership to develop novel antiviral agents including dengue virus, influenza and others.
Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue hemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications.
Market Dynamics: Dengue Treatment Market
Global dengue treatment market anticipated surging its growth owing to rise in dengue burden in tropical and sub-tropical regions, increased government funding to fight against dengue, and unmet market needs of managing dengue burden around the world. In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. However, lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and the high-cost of treatment are hindering the dengue-treatment market.
Market Segmentation: Dengue Treatment Market
Dengue Treatment Market has been segmented on the basis of drug class and distribution channel
Based on drug class, dengue Treatment market is segmented into
- NSAIDS
- Antibiotics
- Corticosteroids
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Dengue Treatment market is expected to grow at a significant rate during forecast period. According to World Health Organization (WHO) estimates, 50 to 100 Mn infections occur annually, including 500,000 DHF cases and 22,000 deaths, mostly among children. Dengue treatment market is at developing stage. Market players collaborating to other companies or research institutions for the development of drugs for treating the dengue. For instance, in August 2013, Johnson and Johnson Services Inc. collaborated with biotechnology nonprofit organization The Wellcome Trust, for the development of prevention and treatment therapies for dengue fever.
Regional Overview: Dengue Treatment Market
Geographically Dengue Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East &Africa. Latin America market expected to grow owing to increased dengue cases. According to WHO, in 2010, 1.6 million cases of dengue were reported in the Americas alone. In Asia-Pacific region, dengue treatment market expected to grow at a high rate due to increase in dengue coupled with an increase in government funding for dengue prevention and treatment. Market players in Asia are actively participating in develepment of dengue treating drugs to increase their market share. For instance, in May 2016, Sun Pharma collaborated with International Centre of Genetic Engineering and Biotechnology (ICGEB) to develep drug for treatment of dengue. South East Asia and Western Pacific regions are more seriously affected by dengue. Hence, companies are planning to launch their vaccines in South East Asia regions.
Market Participants: Dengue Treatment Market
Some of the market players in Dengue treatment market include F. Hoffmann-La Roche AG (Switzerland), Sun Pharmaceutical Industries Limited (India), Abbivax (France), Takeda Pharmaceutical Company Ltd (Japan), Merck & Co Inc. (U.S.), and VABIOTECH (Vietnam) to name a few.
Key Market Developments: Dengue Treatment Market
In September 2017, Abbivax and Evotec AG entered into strategic partnership to develop novel antiviral agents including dengue virus, influenza and others.
1. EXECUTIVE SUMMARY
2. GLOBAL DENGUE TREATMENT MARKET INTRODUCTION
2.1. Global Dengue Treatment Market – Taxonomy
2.2. Global Dengue Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. GLOBAL DENGUE TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dengue Treatment Market Dynamic Factors - Impact Analysis
4. GLOBAL DENGUE TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL DENGUE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. NSAIDS
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antibiotics
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Corticosteroids
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Oral
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL DENGUE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. NSAIDS
9.1.2. Antibiotics
9.1.3. Corticosteroids
9.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Pareneteal
9.2.3. Others
9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Dengue Treatment Market Dynamics – Trends
10. EUROPE DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. NSAIDS
10.1.2. Antibiotics
10.1.3. Corticosteroids
10.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Pareneteal
10.2.3. Others
10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Dengue Treatment Market Dynamics – Trends
11. ASIA-PACIFIC DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. NSAIDS
11.1.2. Antibiotics
11.1.3. Corticosteroids
11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Pareneteal
11.2.3. Others
11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Dengue Treatment Market Dynamics – Trends
12. LATIN AMERICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. NSAIDS
12.1.2. Antibiotics
12.1.3. Corticosteroids
12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Pareneteal
12.2.3. Others
12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Dengue Treatment Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. NSAIDS
13.1.2. Antibiotics
13.1.3. Corticosteroids
13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Pareneteal
13.2.3. Others
13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.6. MEA Dengue Treatment Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche AG (Switzerland)
14.2.2. Sun Pharmaceutical Industries Limited (India)
14.2.3. Abbivax (France)
14.2.4. Takeda Pharmaceutical Company Ltd (Japan)
14.2.5. Merck & Co Inc. (U.S.)
14.2.6. VABIOTECH (Vietnam)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL DENGUE TREATMENT MARKET INTRODUCTION
2.1. Global Dengue Treatment Market – Taxonomy
2.2. Global Dengue Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. GLOBAL DENGUE TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dengue Treatment Market Dynamic Factors - Impact Analysis
4. GLOBAL DENGUE TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL DENGUE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. NSAIDS
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antibiotics
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Corticosteroids
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Oral
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL DENGUE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. NSAIDS
9.1.2. Antibiotics
9.1.3. Corticosteroids
9.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Pareneteal
9.2.3. Others
9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Dengue Treatment Market Dynamics – Trends
10. EUROPE DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. NSAIDS
10.1.2. Antibiotics
10.1.3. Corticosteroids
10.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Pareneteal
10.2.3. Others
10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Dengue Treatment Market Dynamics – Trends
11. ASIA-PACIFIC DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. NSAIDS
11.1.2. Antibiotics
11.1.3. Corticosteroids
11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Pareneteal
11.2.3. Others
11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Dengue Treatment Market Dynamics – Trends
12. LATIN AMERICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. NSAIDS
12.1.2. Antibiotics
12.1.3. Corticosteroids
12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Pareneteal
12.2.3. Others
12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Dengue Treatment Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. NSAIDS
13.1.2. Antibiotics
13.1.3. Corticosteroids
13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Pareneteal
13.2.3. Others
13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.6. MEA Dengue Treatment Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche AG (Switzerland)
14.2.2. Sun Pharmaceutical Industries Limited (India)
14.2.3. Abbivax (France)
14.2.4. Takeda Pharmaceutical Company Ltd (Japan)
14.2.5. Merck & Co Inc. (U.S.)
14.2.6. VABIOTECH (Vietnam)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
